Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis, Epstein-Barr Virus Infections
Epstein-Barr Virus Antibodies in Egyptian Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system that causes variable degrees of neurological disability.
- Conditions
- Multiple Sclerosis, Epstein-Barr Virus Infections, Epstein-Barr Virus (EBV) Infection
- Trial name
- NCT07846943
- Volunteers
- 140 people
- Sponsor
- Assiut University
Multiple Sclerosis
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Primary Objective: To evaluate the efficacy, safety, and tolerability of alemtuzumab intravenously (IV) in pediatric participants from 10 to less than (<) 18 years of age with Relapsing Remitting Multiple Sclerosis (RRMS) who…
- Trial name
- LemKids (NCT03368664)
- Testing
- Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon
- Where
- 13 sites in France, Italy and 4 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07305116
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Neurodegenerative Diseases, Cognitive Decline
The Efficacy of VESPA 2.0 for Cognitive Rehabilitation in Patients With Mild Cognitive Impairment
VESPA 2.0 is based on an integrative and ecological approach used for the treatment of cognitive dysfunction in patients with MCI or other neurodegenerative disorders.
- Conditions
- Neurodegenerative Diseases, Cognitive Decline, Parkinson Disease Dementia, Alzheimer Disease
- Trial name
- NCT06281314
- Testing
- Vespa software
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Multiple Sclerosis, Relapsing-remitting
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects
This is a randomized, multicenter, parallel-group, open-label study comparing the tolerability of Rebif® injections (44 microgram [mcg] administered subcutaneously three times a week) with and without Rebiject™Mini, an…
- Trial name
- NCT00292253
- Testing
- Rebif® via Rebiject™Mini, Rebif® via manual injections
- Volunteers
- 1,883 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
Primary Objective: Evaluate the relationship between ABCG2 mutation (rs2231142) and teriflunomide exposure, during 6-month treatment with teriflunomide 14 mg Secondary Objective: Characterize the safety (AEs, such as ALT…
- Trial name
- TERI-PK (NCT04410965)
- Testing
- TERIFLUNOMIDE
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Sanofi
Multiple Sclerosis
Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis
Randomized, double-blind, placebo-controlled Phase IIa clinical study, assessing safety, tolerability, pharmacodynamic effects and pharmacokinetics of temelimab, administered at three different dose levels (18 mg/kg or 36 mg/kg…
- Trial name
- ProTEct-MS (NCT04480307)
- Testing
- temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg
- Where
- Sweden
- Volunteers
- 41 people
- Sponsor
- GeNeuro Innovation SAS
Multiple Sclerosis
Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis
The objective of the present investigator-initiated mono-center trial to be performed at the Department of Neurology of the University Hospital Zurich is a detailed characterization of the effects of prolonged-release fampridine…
- Trial name
- FAMPKIN (NCT01576354)
- Testing
- Prolonged-release Fampridine
- Where
- Switzerland
- Volunteers
- 70 people
- Sponsor
- University of Zurich
Multiple Sclerosis
Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis
This study assesses clinical and imaging long-term data, after early or delayed interferon-beta-1b treatment in patients with a first demyelinating event suggestive of multiple sclerosis (MS), 11 years after enrollment in the…
- Trial name
- NCT01795872
- Testing
- Several diagnostic procedures
- Where
- 77 sites in Austria, Belgium and 18 more
- Volunteers
- 278 people
- Sponsor
- Bayer
Multiple Sclerosis
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
- Trial name
- NCT01892722
- Testing
- Interferon beta-1a, Fingolimod
- Where
- 73 sites in United States, Australia and 23 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Tuberous Sclerosis, Angiofibroma
Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex
The purpose of this trial is to evaluate the safety and efficacy of long-term treatment with NPC-12G gel (0.2% sirolimus gel) to angiofibroma and other skin lesions in patients with tuberous sclerosis complex in the open-label…
- Conditions
- Tuberous Sclerosis, Angiofibroma, Hypomelanotic Macule, Plaque
- Trial name
- NCT02634931
- Testing
- NPC-12G gel
- Where
- Japan
- Volunteers
- 94 people
- Sponsor
- Nobelpharma
Progressive Multiple Sclerosis
Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
To evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple sclerosis without relapse.
- Trial name
- MAXIMS (NCT05441488)
- Testing
- Masitinib (4.5)
- Where
- 37 sites in France, Greece and 6 more
- Volunteers
- 800 people
- Sponsor
- AB Science
Multiple Sclerosis
Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis
The aim of this study is the development of novel telemedical examination methods based on sensor-based gait analysis in patients with multiple sclerosis (MS).
- Trial name
- MSgoesHome (NCT04771858)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medical Valley Digital Health Application Center GmbH
Tuberous Sclerosis Complex (TSC)
Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous Sclerosis
Observational, retrospective, multicenter, nonprofit study on the prevalence of renal involvement in pediatric patients with tuberous sclerosis.
- Trial name
- NCT06764602
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Multiple Sclerosis
Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM)
Sphingosine 1-Phosphate (S1P) receptor modulators (S1PRMs) are part of the evolving treatment landscape of Multiple Sclerosis (MS) immunotherapies.
- Trial name
- PATTERN (NCT05828901)
- Testing
- S1PR analysis on immune cells
- Where
- Switzerland
- Volunteers
- 23 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple Sclerosis
Neurodynamic Interventions for Multiple Sclerosis
A randomized, parallel-group, clinical trial will be conducted to compare the immediate effects of the inclusion of a neurodynamic intervention into a multimodal physiotherapy program on pressure pain sensitivity, pain and manual…
- Trial name
- NCT03595631
- Testing
- Physical Therapy, Physical Therapy plus Neurodynamic
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- Universidad Rey Juan Carlos
Spasticity in Participants With Multiple Sclerosis
Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols as adjunctive therapy compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Modified Ashworth Scale…
- Trial name
- RELEASE MSS1 (NCT04657666)
- Testing
- Nabiximols
- Where
- 16 sites in Czechia, Poland
- Volunteers
- 68 people
- Sponsor
- Jazz Pharmaceuticals
Relapsing Remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
Noninvasive brain stimulations (NIBS) will be used in MS patients with cognitive impairments to enhance their cognitive aptitudes.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Cognitive Deficits, Motor Deficits
- Trial name
- MScog-tDCS (NCT02266121)
- Testing
- tDCS
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital of Mont-Godinne
Multiple Sclerosis
Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies
Vaccine responses in patients treated with anti-CD20 antibodies (ocrelizumab and ofatumumab) or S1P receptor modulators (fingolimod and siponimod) were evaluated before and after third SARS-CoV-2 vaccination as part of an ongoing…
- Trial name
- NCT05950308
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Interoception and Sense of Movement in the Patient With Multiple Sclerosis
To evaluate the effectiveness of an experimental rehabilitative protocol with specific tasks for the improvement of body awareness and the motor scheme in the patient with multiple sclerosis (EDSS <2.5).
- Trial name
- NCT03711968
- Testing
- Rehabilitative treatment protocol
- Where
- Italy
- Volunteers
- 63 people
- Sponsor
- University of Roma La Sapienza
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.